Key result
Warfarin added to dual antiplatelet therapy after PCI significantly increased the risk of major bleeding compared to dual antiplatelet therapy alone (HR 5.0; 95% CI 1.4-17.8; p=0.012).
Why the study?
Does the addition of warfarin to dual antiplatelet therapy increase the risk of major bleeding in patients after percutaneous coronary intervention?
Cohort (n=194)
No
Does the addition of warfarin to dual antiplatelet therapy increase the risk of major bleeding in patients after percutaneous coronary intervention?
The use of warfarin in combination with dual antiplatelet therapy after PCI is associated with a 5-fold increased risk of major bleeding compared to dual antiplatelet therapy alone.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
DeEugenio et al. (2007) conducted a cohort in Percutaneous coronary intervention (n=194). Warfarin (with aspirin and clopidogrel) vs. Aspirin and clopidogrel was evaluated on Major bleeding (HR 5.0, 95% CI 1.4-17.8, p=0.012). Warfarin added to dual antiplatelet therapy after PCI significantly increased the risk of major bleeding compared to dual antiplatelet therapy alone (HR 5.0; 95% CI 1.4-17.8; p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: